Logo-npj
Submitted: 19 Dec 2022
Accepted: 05 Mar 2023
ePublished: 16 May 2023
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)

J Nephropharmacol. 2023;12(2): e10577.
doi: 10.34172/npj.2023.10577

Scopus ID: 85162068753
  Abstract View: 948
  PDF Download: 402

Original

Effectiveness of corticosteroid therapy in patients with moderate to severe coronavirus disease 2019: a retrospective study

Sara Sadeghi 1 ORCID logo, Marjan Mansourian 2 ORCID logo, Sara Ebrahimi 3, Baran Kahid Basiri 4 ORCID logo, Niloofar Nikgoftar 5 ORCID logo, Soheila Jalali 2 ORCID logo, Ramin Sami 6* ORCID logo

1 Medical Student, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
2 Department of Epidemiology and Biostatics, School of Health, Isfahan University of Medical Sciences, Isfahan, Iran
3 Alzahra Research Institute, Alzahra University Hospital Isfahan University of Medical Sciences Isfahan, Iran
4 General Practitioner, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
5 General Physician, Department of Family and Emergency Medicine, Faculty of Medicine, Isfahan University of Medical Science, Isfahan, Iran
6 Department of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
*Corresponding Author: Ramin Sami, Email: r.sami@med.mui.ac.ir

Abstract

Introduction: Ne An acute respiratory infection started in Wuhan city of China in December 2019. The pathogen was discovered as a novel coronavirus from the Coronaviridae family and called the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). According to clinical symptoms and laboratory tests, coronavirus disease 2019 (COVID-19) patients are categorized as asymptomatic, mild, moderate, severe and critical state. Suggested therapies used in moderate to severe COVID-19 disease include corticosteroids, anticoagulation and antiviral drugs (e.g., remdesivir).

Objectives: We reviewed the clinical outcomes associated with corticosteroid treatment for COVID-19.

Patients and Methods: We planned a retrospective study with 859 patients diagnosed with SARS-CoV-2 infection who were under treatment at Khorshid hospital affiliated with Isfahan University of Medical Sciences, Isfahan, Iran (from February to May 2020).

Results: A total of 859 patients were included in this study. The mean age was 63.33±15.45 years of which 43.8% (n=376) were women. We subcategorized corticosteroids by dose prescribed in smaller groups to show better results. The secondary outcome including the rate of intensive care units (ICUs) admission and death was less with corticosteroid prescription. This study showed, mortality and ICU admission were fewer in patients with ≥51 mg/d and ≥201 mg/d of methylprednisolone therapy, respectively.

Conclusion: Based on this study, corticosteroid treatment can reduce both the need for ICU admission and mortality in moderate to severe COVID-19 patients. However, clinical trials are needed to investigate the effect of corticosteroid therapy on the need to mechanically ventilate a patient.


Implication for health policy/practice/research/medical education:

The effectiveness of corticosteroid treatment in reducing the hospitalization rate in the ICU and reducing the mortality of moderate to severe COVID-19 patients.

Please cite this paper as: Sadeghi S, Mansourian M, Ebrahimi S, Kahid Basiri B, Nikgoftar N, Jalali S, Sami R. Effectiveness of corticosteroid therapy in patients with moderate to severe coronavirus disease 2019: a retrospective study. J Nephropharmacol. 2023;12(2):e10577. DOI: 10.34172/npj.2023.10577.

First Name
 
Last Name
 
Email Address
 
Comments
 
Security code


Abstract View: 949

Your browser does not support the canvas element.


PDF Download: 402

Your browser does not support the canvas element.